Abstract
A live attenuated varicella-zoster vaccine (Zostavax--Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons > or = 60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
MeSH terms
-
Adult
-
Age Factors
-
Drug Approval
-
Herpes Zoster / drug therapy*
-
Herpes Zoster / immunology
-
Herpes Zoster / virology
-
Herpes Zoster Vaccine
-
Herpesvirus Vaccines / adverse effects
-
Herpesvirus Vaccines / immunology
-
Herpesvirus Vaccines / therapeutic use*
-
Humans
-
Injections, Subcutaneous
-
Middle Aged
-
Neuralgia, Postherpetic / etiology
-
Population Surveillance
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Time Factors
-
United States
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / immunology
-
Vaccines, Attenuated / therapeutic use
Substances
-
Herpes Zoster Vaccine
-
Herpesvirus Vaccines
-
Vaccines, Attenuated